10/28/2026
Today, the rare disease community was a united force at the launch of the stakeholder engagement process to inform FDA’s new framework for rare disease drug development and regulatory review.
With more than 2,800 virtual participants, over 200 attendees, and more than 70 members of the rare stakeholder community providing testimony, today’s input underscored the urgency, unmet need, and near-term opportunities in our rare therapy development pipelines.
In her testimony today, Annie Kennedy, Chief Mission Officer with the RARE Foundation, highlighted the importance of including rare disease subpopulations and teams of reviewers with diverse backgrounds. "Today signifies an inflection point in rare disease – and our community is eager to partner with FDA to harness the potential in our pipelines to create a system that ensures that no individual living with rare disease is too rare."
James Valentine, member of our Board of Directors and Director at Hyman, Phelps & McNamara, also testified to the needs of the rare disease community, "We also believe the framework must recognize that rarity is a continuum, not a set of categories. While a disease affecting tens of patients may seem to present more acute challenges than one affecting a thousand, 10,000, or even 200,000, the challenges across that continuum are often more alike than different."
To hear more about key themes from today and opportunities to engage, join the RARE Advocates webinar Friday, October 30th at 12 noon ET. Register here: https://www.rareadvocates.org/events/rare-advocates-webinar/
To learn more about the initiative and what it means for the rare disease community, visit our website: https://www.rareadvocates.org/news/fda-introduces-a-new-framework-for-rare-disease-review/
Pictured: Kyle Diamantas, Acting FDA Commissioner